Bullfrog AI providing AI solution for Eleison Pharmaceuticals Phase 3 trials

BullFrog AI (BFRG) announced its entry into a collaboration agreement with Eleison Pharmaceuticals, a Phase 3 oncology company focused on novel chemotherapeutic treatments for rare cancers, under which BullFrog AI will provide access to its BullFrog Data Networks AI solution to enhance clinical trial efficiency and patient insights. Financial terms of the collaboration were not disclosed. Through this collaboration, BullFrog AI will apply its proprietary BullFrog Data Networkssolution, powered by the bfLEAP platform, to analyze clinical data from Eleison’s ongoing Phase 3 trial and previous clinical studies of glufosfamide, an investigational treatment for pancreatic cancer. Eleison expects to complete this ongoing Phase 3 trial in 2027.